Un informe divulga los avances y retos de futuro de las terapias génica y celular

by CIBERER - Centro de Investigación Biomédica en Red de Enfermedades Raras

Un informe coordinado por Juan Bueren, investigador de la U710 CIBERER en el CIEMAT y el IIS-FJD, expone en términos divulgativos qué son las terapias génica y celular, presenta los principales ava...

Read more

ProteoDesign announces new Investment led by Ysios Capital and rebrands as Splice Bio

by Ysios Capital

Splice Bio, a biotech company based on technology developed in the Muir Lab at Princeton University, announced today a new investment into the Company led by Ysios Capital and joined by Asabys Partner...

Read more

The AECC finances the implantation of a new cancer model in C. elegans

by Hospital Universitari de Bellvitge

​The ID​IBELL group led by Dr. Julián Cerón has received an “Ideas Semilla” grant from the Spanish Association Against Cancer (AEC​C). These grants are addressed at innovative projects tha...

Read more

El Hospital Virgen Macarena, centro de referencia autonómico para las enfermedades raras de la retina, atiende un alto número de personas o familias afectas de esta patología

by Hospital Universitario Virgen de la Macarena

La retinosis pigmentosa o pigmentaria es una enfermedad rara que se produce por un daño en unas importantes células de la retina que son los bastones. “El daño se produce por una mutación genét...

Read more

How to industrialize cell and gene therapies?

by Pall Biotech

As gene therapies move towards commercialization, a robust, scalable and affordable manufacturing process is critical to ensure these novel therapies reach the patient and that a pipeline of clinical ...

Read more

Purification specialist BIA Separations to become part of Sartorius

by Sartorius Stedim Spain

The life science company Sartorius announced today it has entered into a definitive agreement to merge purification specialist BIA Separations into its subgroup Sartorius Stedim Biotech in a transacti...

Read more

Evalúan la eficacia de terapia génica con nanoanticuerpos de camélidos para la enfermedad de Huntington

by CIBERER - Centro de Investigación Biomédica en Red de Enfermedades Raras

Un equipo multidisciplinar formado por miembros de la U755 C​IBERER en el Instituto de Investigación Sanitaria La Fe (IIS LaFe), la U733 CI​BERER en la Universitat de València y la U​7​39 CI...

Read more

Optogenetic therapy to restore advanced vision loss in retinal dystrophies

by DBGen Ocular Genomics

​ Gene therapies currently under study for retinal dystrophies are administered when viable photoreceptor able to be rescued at the functional level still remain. Most therapies are gene-specific...

Read more

SparingVision Raises €44.5 Million in a round led by 4BIO Capital and UPMC Enterprises, and included Jeito Capital and Ysios Capital

by Ysios Capital

SparingVision (“the Company”), a genomic medicine company focused on ocular diseases, today announces a €44.5 million financing round. The round was led by 4BIO Capital (“4BIO”) and UPMC Ent...

Read more
Subscribe to Directory
Write an Article

Recent News

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

La Unidad de Chequeos de la Clínica sup...

El estudio realizado sobre una muestra significati...

Highlight

Interview with Dámaso Molero, general m...

by 3P Biopharmaceuticals

Dámaso Molero: “There are great opportunities in Latin America for ...

Sistema inmune frente a virus

by Labo'Life

Ante una quemadura en la piel, la picadura de un mosquito, una infecci...

Photos Stream